ArticleScientific reports2025
Nonlinear associations of the hs-CRP/HDL-C index with metabolic dysfunction-associated steatotic liver disease and advanced liver fibrosis in US adults: insights from NHANES 2017-2018.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Association of AGAHR with metabolic dysfunction-associated steatotic liver disease (MASLD).Hormones (Athens, Greece) · 2026Article
- Association of serum uric acid and serum uric acid/creatinine ratio with metabolic dysfunction-associated fatty liver disease in young adults: a retrospective study.BMC endocrine disorders · 2026Article
- Remnant cholesterol inflammatory index and MASLD in U.S. adults: mediation role of triglyceride-glucose index.Journal of clinical & translational endocrinology · 2026Article
- Biomarkers for early identification of metabolic dysfunction-associated steatotic liver disease (MASLD): a narrative review.Archives of medical science : AMS · 2026Article
- Diagnostic value of serum 25-hydroxyvitamin D, hs-CRP, and adiponectin metabolic dysfunction-associated steatotic liver disease in patients with severe obesity: a retrospective study.American journal of translational research · 2026Article
- Article
- Article
- S-shaped association between hs-CRP/HDL-C index and overweight/obesity in children and adolescents: a population-based study.European journal of medical research · 2025Article
- High Myopia as a Risk Factor for Severe Liver Disease in Individuals with Liver Dysfunction: Evidence from a Prospective Cohort.Journal of clinical medicine · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease Is Characterized by Enhanced Endogenous Cholesterol Synthesis and Impaired Synthesis/Absorption Balance.International journal of molecular sciences · 2025Article
- Association between hs-CRP/HDL-C ratio and risk of prediabetes or diabetes: a cross-sectional study based on NHANES 2015-2023.BMC endocrine disorders · 2025Article
- Hs-CRP/HDL-C ratio as a predictive inflammatory-lipid marker for sarcopenia: evidence from NHANES 2015-2018.Frontiers in immunology · 2025Article
- Cross-sectional association between hs-CRP/HDL-C ratio and physical frailty among middle-aged and older adults: findings from a population-based study.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a globally widespread chronic liver condition that may progress to severe liver diseases, including advanced liver fibrosis. The high-sensitivity C-reactive protein-to-high-density lipoprotein cholesterol (hs-CRP/HDL-C) index may be a potential indicator for MASLD and advanced liver fibrosis, given its relevance to inflammation and plasma lipids. In this study, the hs-CRP/HDL-C index was investigated in relation to prevalent MASLD and advanced liver fibrosis. The study analyzed secondary data from the National Health and Nutrition Examination Survey (NHANES) 2017-2018 database. The hs-CRP/HDL-C index was calculated by the quotient of hs-CRP and HDL-C. Multiple logistic regression models, Cochran-Armitage trend tests, smooth curve fitting, threshold effect analyses, and stratified analyses were used to evaluate whether the hs-CRP/HDL-C index associated with MASLD and advanced liver fibrosis. The study cohort comprised 3684 participants, of whom 1268 (34.42%) were diagnosed with MASLD and 156 (12.28%) with advanced liver fibrosis. Logistic analyses adjusted for covariates revealed positive associations of the hs-CRP/HDL-C index with MASLD and advanced liver fibrosis, consistent across all subgroups. Smooth curve fitting and threshold effect analyses revealed nonlinear relationships of hs-CRP/HDL-C index with MASLD and advanced liver fibrosis, with inflection points at 0.8 for MASLD and 1.2 for advanced liver fibrosis. Additionally, significant interactions were observed between MASLD and covariates such as gender, smoking status, chronic kidney disease (CKD), and cancer. Similarly, the hs-CRP/HDL-C index exhibited positive correlations with advanced liver fibrosis across diverse subgroups, with notable interactions related to cancer. MASLD and advanced liver fibrosis were associated with hs-CRP/HDL-C index, indicating its potential utility as a clinical marker for these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.